Sacituzumab govitecan for previously treated advanced non-small cell lung cancer

Sacituzumab govitecan is in development for advanced or metastatic non-small cell lung cancer (NSCLC), that has progressed on or after previous therapies with platinum-based chemotherapy and immunotherapy. NSCLC is the most common type of lung cancer accounting for 80-85% of lung cancers. Most common symptoms include a cough, recurrent chest infections, coughing up blood, tiredness or lack of energy, and loss of appetite. Advanced or metastatic cancer is incurable and has spread from its original area in the lung to other parts of the body. Although outcomes for patients with NSCLC have been improved over the last decade, the probability of a cure in the advanced setting is rare. Therefore, there is a great unmet need to provide more effective therapeutic strategies to further improve outcome in patients with advanced NSCLC.